Obama Thinks "Precision Medicine" Will Make Us Healthier. Experts are Skeptical.
By Julia Belluz,
Vox
| 01. 30. 2015
Untitled Document
The White House is committing $215 million to support efforts to develop personalized medicine, a priority the President touched on in his State of the Union earlier this month.
At the time, the details weren't clear. But today the White House released more information on the "precision medicine initiative," which has bipartisan support: it would get started with a $215 million cash injection from the 2016 federal budget to support everything from the building databases at the National Institutes of Health to study the genetic bases of disease, to applying that knowledge to targeted cancer therapeutics and public health.
"Most medical treatments have been designed for the 'average patient,'" the White House statement read. "As a result of this 'one-size-fits-all-approach,' treatments can be very successful for some patients but not for others."
The only problem is that this is much, much harder than it sounds.
Precision medicine — also known as personalized or individualized medicine — has been one of the big, unmet promises in health care for a long time. Hank Greely, a law professor at Stanford...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 09.08.2026
It is one of biology’s most ingenious rhythms: Every baby is born young. No matter how much wear and tear their parents’ DNA accumulated over their lifetimes, reproduction erases the molecular scars, handing a clean slate to the next generation...
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Jessica Hamzelou, MIT Technology Review | 07.23.2026
When it comes to organ donation, time is everything. As soon as an organ has been carefully removed from a donor’s body, it starts to deteriorate. Surgeons have a matter of hours to get it into a recipient. Leave...